Dysfonction érectile chez les patients diabétiques type 2, prévalence et gravité au Service d´Urologie du Centre Hospitalier Universitaire de Fès, Maroc: à propos de 96 cas (étude transversale)

INTRODUCTION: type 2 diabetes is a very common condition which, in some patients, may cause erectile dysfunction. The purpose of this study is to determine the prevalence and severity of erectile dysfunction in patients with type 2 diabetes attending the Department of Urology. METHODS: we conducted a cross-sectional and descriptive study in the Department of Urology at the University Hospital Center Hassan II in Fez using a self-administered questionnaire encompassing an “International Index of Erectile Function-5” test based on 5 questions with routine blood test results in diabetic patients. RESULTS: a total of 96 anonymous questionnaires were distributed over a 12-month period. The average age of patients was 53.5 years, 35% (n=34) of them were active smokers. Diabetes had progressed for over 10 years in 54% (n=52) of cases. Three patients were treated with diet alone, 32% (n=31) with oral antidiabetic drugs, 31% (n=30) with insulin therapy alone and 31% (n=30) with insulin and oral antidiabetic drugs. Only 11% (n=11) of patients had HbA1c below 7%. Patients reporting erectile dysfunction accounted for 70% (n=67) of surveyed patients. The proportion of patients with erectile dysfunction according to the International Index of erectile function-5 was 88% (n=84). The onset of erectile dysfunction had started more than 3 years earlier in 63% (n=60) of patients. Disorders started progressively in 90% (n=86) of patients. Screening rate was 37.5% (n=36), only 30% (n=29) of patients received phosphodiesterase type 5 inhibitors, then intracavernous injection or both. Forty-two per cent (n=40) of patients had either macro or micro-angiopathic complications. CONCLUSION: erectile dysfunction is a common but little suspected condition in diabetic men. Hence, the importance of systematic screening in any diabetic patient and of adequate treatment for sexual and cardiovascular disorders.